Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011) - 16/07/18
, James M. Farnham, PhD c, John Hyngstrom, MD b, e, Marki E. Klapperich, BS f, Aaron M. Secrest, MD, PhD a, Sarah Empey, BS e, Glen M. Bowen, MD a, e, David Wada, MD a, e, Robert H.I. Andtbacka, MD b, e, Kenneth Grossmann, MD, PhD c, e, Tawnya L. Bowles, MD b, Lisa A. Cannon-Albright, PhD c, e, gAbstract |
Background |
Survival data are mixed comparing patients with multiple primary melanomas (MPM) to those with single primary melanomas (SPM).
Objectives |
We compared MPM versus SPM patient survival using a matching method that avoids potential biases associated with other analytic approaches.
Methods |
Records of 14,138 individuals obtained from the Surveillance, Epidemiology, and End Results registry of all melanomas diagnosed or treated in Utah between 1973 and 2011 were reviewed. A single matched control patient was selected randomly from the SPM cohort for each MPM patient, with the restriction that they survived at least as long as the interval between the first and second diagnoses for the matched MPM patient.
Results |
Survival curves (n = 887 for both MPM and SPM groups) without covariates showed a significant survival disadvantage for MPM patients (chi-squared 39.29, P < .001). However, a multivariate Cox proportional hazards model showed no significant survival difference (hazard ratio 1.07, P = .55). Restricting the multivariate analysis to invasive melanomas also showed no significant survival difference (hazard ratio 0.99, P = .96).
Limitations |
Breslow depth, ulceration status, and specific cause of death were not available for all patients.
Conclusions |
Patients with MPM had similar survival times as patients with SPM.
Le texte complet de cet article est disponible en PDF.Key words : melanoma, multiple primary, SEER, survival
Abbreviations used : HR, MPM, SPM, SEER
Plan
| Drs Grossman and Farnham contributed equally. |
|
| Dr Grossman is supported by the University of Utah Department of Dermatology and the Huntsman Cancer Foundation. Dr Cannon-Albright is supported by the Huntsman Cancer Foundation and the U.S. Department of Veterans Affairs. This research was supported by the Utah Cancer Registry, which is funded by Contract No. HHSN261201000026C from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program with additional support from the Utah State Department of Health and the University of Utah. Research reported was also supported by the National Cancer Institute of the National Institutes of Health under award numbers P30CA042014 and CA195614 (to Dr Cannon-Albright). |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 79 - N° 2
P. 238-244 - août 2018 Retour au numéro
Article précédent
- Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children
- Jennifer T. Huang, Johanna S. Song, Elena B. Hawryluk, Wendy B. London, Dongjing Guo, Madhumitha Sridharan, David E. Fisher, Leslie E. Lehmann, Christine N. Duncan
- The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex
- Andrew J. Sinnamon, Cimarron E. Sharon, Yun Song, Madalyn G. Neuwirth, David E. Elder, Xiaowei Xu, Emily Y. Chu, Michael E. Ming, Douglas L. Fraker, Phyllis A. Gimotty, Giorgos C. Karakousis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?